Medtronic (MDT) Q4 2026 earnings review
Decade-High Revenue Growth Masked by Severe Margin Compression
Medtronic delivered its strongest top-line performance in ten years, with Q4 organic revenue accelerating to 6.6%. The Cardiac Ablation Solutions (CAS) business is achieving hypergrowth (+78% globally) on the back of its PFA portfolio. However, the cost of capturing this market share has been steep. Q4 Non-GAAP operating margin plummeted 230 basis points, dragging Non-GAAP EPS down 4.3% YoY to $1.55. Management is guiding for a powerful FY27, forecasting accelerating revenue (6.75%-7.25%) and a rebound in EPS growth (6.7%-8.5%), but investors must weigh the promised future leverage against the current reality of tariff headwinds, heavy launch investments, and dilutive product mix.
🐂 Bull Case
Medtronic has successfully accelerated organic growth throughout FY26 (4.8% in Q1 to 6.6% in Q4). The pipeline is delivering, and FY27 guidance implies further acceleration, an impressive feat for a mega-cap medical device company.
The company is not just taking share; it is unlocking entirely new multi-billion dollar TAMs. Symplicity for hypertension (18M US patients) and Altaviva for incontinence (16M US patients) provide a long runway for durable growth.
🐻 Bear Case
The explosive 78% growth in CAS is heavily driven by lower-margin capital equipment placements. Until this installed base transitions to high-margin consumable catheter sales, gross margins will continue to suffer.
Tariffs remain a relentless headwind, shaving 80 basis points off Q4 operating margins. Combined with increased G&A required for new product launches, the promised operational leverage remains elusive.
⚖️ Verdict: ⚪
Neutral. The pipeline execution is undeniably excellent, and the revenue acceleration is real. However, the severe margin degradation—driven by product mix, tariffs, and launch investments—means investors are paying for top-line growth that isn't yet reaching the bottom line.
Key Themes
Cardiac Ablation Solutions (CAS) Hypergrowth
The Pulsed Field Ablation (PFA) portfolio is a blockbuster. CAS revenue skyrocketed 78% globally and an astonishing 124% in the U.S. in Q4, gaining an estimated 8 points of U.S. market share. This franchise is single-handedly pulling the Cardiovascular segment up (+10.1% organic) and acting as the primary engine for Medtronic's enterprise-wide acceleration.
Severe Margin Compression Contradicts 'Decade-High' Narrative
While management proudly highlighted the 'strongest annual top-line growth in 10 years,' the profitability metrics tell a darker story. Q4 Non-GAAP operating margin plummeted by 230 basis points to 25.5%. This drop was driven by a vicious combination of product mix (lower-margin capital equipment in CAS), an 80 basis point hit from tariffs, and a 160 basis point impact from a MiniMed Blackstone payment. Growth is currently coming at the direct expense of margins.
Generational Product Launches Scaling Up
Beyond CAS, Medtronic is activating several massive growth vectors. The Symplicity RDN system is tapping into the 18 million U.S. patient market for uncontrolled hypertension. Meanwhile, the Altaviva system for urinary incontinence is ramping. These are not incremental updates; they are distinct, multi-billion-dollar market creation opportunities.
Diabetes Separation Appears Delayed
In late FY25 and early FY26, management confidently guided that the separation of the Diabetes business would be completed within 15-18 months (by late calendar 2026). However, the new FY27 guidance explicitly 'assumes consolidation of the Diabetes business for the full 12 months of FY27.' This suggests the margin-accretive spin-off has been delayed, keeping lower-margin revenue on the books longer than investors anticipated.
Aggressive Tuck-In M&A Strategy Activated
Medtronic is aggressively utilizing its balance sheet to acquire growth. The company completed the acquisition of CathWorks (Coronary/RDN) and announced intentions to acquire Scientia Vascular (Neurovascular) and SPR Therapeutics (Neuromodulation). This pivot toward securing adjacent, high-growth assets signals a willingness to buy innovation rather than rely solely on internal R&D.
Robotic Surgery Footprint Expanding
The Hugo Robotic-Assisted Surgery (RAS) system is taking critical steps forward. The company officially filed its submission to the U.S. FDA for Hugo for both general surgery and gynecologic indications, alongside the LigaSure RAS vessel sealer. If cleared, this massively expands Hugo's addressable procedures in the U.S., transitioning it from a urology-focused tool to a broad surgical platform.
Macro Picture: Persistent Tariff Drag
Global trade friction is directly impacting Medtronic's bottom line. Tariffs shaved 50 basis points off the full-year FY26 operating margin and 80 basis points off Q4 specifically. Management's FY27 guidance explicitly notes that tariffs will continue to be a headwind. The company has limited ability to pass these costs through to hospital systems via pricing.
Other KPIs
Stable. Up 4.6% year-over-year. Represents a healthy free cash flow conversion from non-GAAP net earnings of 76%. This cash generation fully supported the aggressive capital return program, allowing the company to return $4.2 billion to shareholders during the fiscal year.
Accelerating. Grew 5.1% organically, led by low-double-digit growth in Acute Care & Monitoring and high-single-digit growth in Endoscopy. This is a vital acceleration for a segment that historically dragged down the corporate average (growing only 0.8% organic in FY25).
Stable to Decelerating. Grew 3.0% organically in Q4, which is softer than the 5.2% organic growth seen in FY25. Cranial & Spinal Technologies and Neuromodulation both posted low-single-digit growth, indicating that the portfolio requires upcoming launches (like Stealth AXiS) to re-accelerate.
Guidance
Accelerating vs the 5.8% organic growth achieved in FY26. It's important to note this guidance includes the benefit of a 53rd week, which artificially inflates the year-over-year comparison slightly, but underlying momentum remains highly robust.
Accelerating drastically. The midpoint ($5.95) implies 7.6% growth over FY26's $5.53. This is a massive inflection compared to the mere 0.7% EPS growth generated in FY26. Management assumes consolidation of the Diabetes business for the full 12 months, and the guidance absorbs impacts from tariffs, increased M&A, interest, and tax expenses.
Key Questions
Diabetes Separation Timeline
Your FY27 guidance explicitly assumes the consolidation of the Diabetes business for the full 12 months. Does this imply a formal delay to the planned split-off timeline discussed previously, and how does this affect the expected 50-100 bps margin accretion?
Margin Inflection Point for CAS
With the massive 78% growth in Cardiac Ablation Solutions driven largely by PFA capital equipment, when exactly do you expect the installed base to reach critical mass so that high-margin consumable catheter sales can reverse the current mix-driven margin dilution?
53rd Week Impact
Can you quantify the exact basis point contribution of the 53rd week to both the 6.75%-7.25% FY27 organic revenue growth guidance and the high-single-digit EPS growth guidance?
Tariff Mitigation Strategy
With tariffs acting as an 80 basis point headwind to Q4 operating margins, what specific supply chain or manufacturing realignments are underway in FY27 to structurally mitigate this risk, rather than just absorbing it?